Budd–Chiari syndrome

Zylox-Tonbridge's ZENFlow Tiger™ LD PTA Dilatation Catheter Receives ANVISA Marketing Approval

Retrieved on: 
Thursday, August 31, 2023
ANVISA, Ageing, YOY, Budd–Chiari syndrome, Patient, OEM, Pharmaceutical industry, Medical device

HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter (hereinafter referred to as "ZENFlow Tiger™"), a product independently developed by the Company, has received marketing approval from ANVISA.

Key Points: 
  • HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter (hereinafter referred to as "ZENFlow Tiger™"), a product independently developed by the Company, has received marketing approval from ANVISA.
  • Its braided delivery shaft provides outstanding pushability and kink resistance, while the low-temperature molding technology ensures excellent non-compliance.
  • With its unique tapered tip and short shoulder design, ZENFlow Tiger™ can facilitate access through complex lesions and maximize protection of normal blood vessels.
  • Additionally, a coaxial catheter shaft design allows ZENFlow Tiger™ to inflate and deflate rapidly, and it is available in a wide range of sizes for different clinical needs.

MGM Healthcare gives 'second life' to Jordan man with rare genetic disorder

Retrieved on: 
Thursday, December 8, 2022
Altruism, Heart, Old Operating Theatre Museum and Herb Garret, BCS, Blood, Patient, Anticoagulant, Inferior vena cava, Paroxysmal nocturnal hemoglobinuria, Critical care, Associate Director of National Intelligence and Chief Information Officer, Institute of Liver and Biliary Sciences, Liver, USGBC, Bed, Budd–Chiari syndrome, PNH, Tamil Nadu Government Multi Super Speciality Hospital, Liver failure, Hemolysis, Genetic disorder, MGM, Male, Dentistry

CHENNAI, India and AMMAN, Jordan, Dec. 8, 2022 /PRNewswire/ -- Institute of liver diseases and transplant, MGM Healthcare, Multi Super Speciality Hospital in Chennai, has successfully treated a 35-year-old male from Jordan with a rare genetic blood disease - Paroxysmal Nocturnal Hemoglobinuria (PNH) (recurrent propensity for clotting and lysis of blood) and Budd-Chiari Syndrome (BCS) a disorder characterised by obstruction of hepatic venous outflow and inferior vena cava reaching up to heart and end stage liver failure.

Key Points: 
  • Dr Thiagarajan Srinivasan said, "The patient's brother donated a part of his liver after ascertaining the absence of genetic disease.
  • Based on our knowledge this is the first time in India, such a complex course of treatment with liver transplant has happened for such a rare genetic disorder with liver failure."
  • The team of specialists at MGM has given a second chance to the 35-year-old man."
  • Born out of a need for altruism, MGM Healthcare is obsessed with bettering patient experiences and improving clinical outcomes through expertise, passion and technology.

MGM Healthcare gives 'second life' to Jordan man with rare genetic disorder

Retrieved on: 
Thursday, December 8, 2022
Altruism, Heart, Old Operating Theatre Museum and Herb Garret, BCS, Blood, Patient, Anticoagulant, Inferior vena cava, Paroxysmal nocturnal hemoglobinuria, Critical care, Associate Director of National Intelligence and Chief Information Officer, Institute of Liver and Biliary Sciences, Liver, USGBC, Bed, Budd–Chiari syndrome, PNH, Tamil Nadu Government Multi Super Speciality Hospital, Liver failure, Hemolysis, Genetic disorder, MGM, Male, Dentistry

CHENNAI, India and AMMAN, Jordan, Dec. 8, 2022 /PRNewswire/ -- Institute of liver diseases and transplant, MGM Healthcare, Multi Super Speciality Hospital in Chennai, has successfully treated a 35-year-old male from Jordan with a rare genetic blood disease - Paroxysmal Nocturnal Hemoglobinuria (PNH) (recurrent propensity for clotting and lysis of blood) and Budd-Chiari Syndrome (BCS) a disorder characterised by obstruction of hepatic venous outflow and inferior vena cava reaching up to heart and end stage liver failure.

Key Points: 
  • Dr Thiagarajan Srinivasan said, "The patient's brother donated a part of his liver after ascertaining the absence of genetic disease.
  • Based on our knowledge this is the first time in India, such a complex course of treatment with liver transplant has happened for such a rare genetic disorder with liver failure."
  • The team of specialists at MGM has given a second chance to the 35-year-old man."
  • Born out of a need for altruism, MGM Healthcare is obsessed with bettering patient experiences and improving clinical outcomes through expertise, passion and technology.

Mursla Announces Key Appointments to Advisory Board

Retrieved on: 
Wednesday, November 17, 2021
Biotechnology, Finance, Surgery, Health, Professional Services, NTA, Gene, Mortality, University, Cancer, Robotics, Biomarker, Budd–Chiari syndrome, COO, Therapy, Bachelor of Engineering, MD, ISEV, Engineering, International Society, ISCT, International Society for Extracellular Vesicles, IFCM, Coronavirus Scientific Advisory Board (Turkey), CEO, Doctor of Philosophy, Exosome, Portal vein thrombosis, Beaujon Hospital, Automation, Liver cancer, Fluid mechanics, University of Duisburg-Essen, Helmy Eltoukhy, Research, Inflammation, AI, Seminal vesicles, Liquid biopsy, Institute of Liver and Biliary Sciences, Hepatocellular carcinoma, Culture, EV, Biotechnology, Synthetic biology, Publication, Diagnosis, Advisory board, Review, Cell, HCC, DNA, DNA sequencing, Patient, Risk, Myriad Genetics, Pharmaceutical industry, Vaccine, Medical imaging

Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.

Key Points: 
  • Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.
  • He used to sit on the scientific advisory board of EVOX Therapeutics.
  • Mursla is a Cambridge-based liquid biopsy company based on a novel tech platform, ExoPheno, which traces diseases in biofluids via exosomes.
  • Using nanoelectronics and bioengineering, Mursla is developing its platform to detect dozens of cancer types with a single blood test, starting with liver cancer surveillance.